A Systematic Review of HER2 Blockade for the Curative Treatment of Gastroesophageal Adenocarcinoma: Successes Achieved and Opportunities Ahead

Over one million cancer related deaths are attributable to esophageal and gastric cancer worldwide annually, ranking third and sixth as most frequent causes of global cancer mortality. [1] Neoadjuvant chemoradiotherapy (nCRT) is commonly used for the treatment of patients with esophageal adenocarcinoma (EAC), while perioperative chemotherapy is often administered to patients with gastric cancer. [1,2] Notwithstanding the benefit gained with multimodality treatment in both cancer types, the prognosis remains dismal with a high distant relapse rate following surgery.[1] Optimization of treatment is thus urgently needed.
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Tags: Anti-tumour Treatment Source Type: research

Related Links:

ConclusionsIn patients with HER2-positive gastric or GEJ adenocarcinoma, the objective response rate to second-line treatment with ramucirumab plus paclitaxel was significantly higher compared to patients with HER2-negative disease. However, an increased response to treatment was not associated with an improvement in OS.
Source: Gastric Cancer - Category: Gastroenterology Source Type: research
Conditions:   Gastric Neoplasms;   Gastroesophageal Adenocarcinoma;   Esophageal Adenocarcinoma Interventions:   Drug: Zanidatamab;   Drug: Tislelizumab;   Drug: Trastuzumab;   Drug: Capecitabine;   Drug: Oxaliplatin;   Drug: Cisplatin;   Drug: 5-Fluorouracil;   Diagnostic Test: In situ hybridization (ISH)-based companion diagnostic assay;   Diagnostic Test: Immunohistochemistry (IHC)-based companion diagnostic assay Sponsors:   Zymeworks Inc.;   BeiGene, Ltd. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Expert Opin Emerg Drugs. 2021 Nov 23. doi: 10.1080/14728214.2021.2010705. Online ahead of print.ABSTRACTINTRODUCTION: Gastric cancer (GC) and gastro-oesophageal junction cancer (GOJC) patients have a poor prognosis with a 5-year relative survival rate of 6% in the metastatic setting. Despite the well-characterized molecular features, patients have been historically considered for treatment with universal and undistinguishing chemotherapies and targeted agents, except for the HER2-positive population and some immunological approaches.AREAS COVERED: In this review we discuss the intrinsic characteristic of GC/GOJC from an ep...
Source: Expert Opinion on Emerging Drugs - Category: Drugs & Pharmacology Authors: Source Type: research
Gastric cancer (GC) remains one of the most common and deadly cancers worldwide, even if its incidence has decreased over time, mainly because of prevention and treatment of Helicobacter pylori infection[1]. Contrarily, the incidence of gastro-esophageal junction (GEJ) adenocarcinomas has increased, attributable to smoking and elevated body mass index (BMI) [2]. Much progress has been made in the management of advanced G/GEJ adenocarcinomas: the identification of molecular sub-groups benefiting from specific therapies (HER2 positive tumors, MSI/dMMR and EBV positive tumors, FGFR amplified tumors, etc)[3 –6], the intr...
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Source Type: research
This article reviews recent randomised clinical trials on systemic treatment of oesophago-gastric cancers in the perioperative and metastatic setting. Recent findings Adding nivolumab to first-line chemotherapy improved survival in patients with metastatic gastric/gastro-oesophageal junction/oesophageal adenocarcinoma with PD-L1 combined positive score (CPS) ≥ five in a global trial and progression-free survival in metastatic gastric/gastro-oesophageal junction cancers in an Asian trial. The addition of pembrolizumab to first-line chemotherapy improved survival in metastatic oesophageal cancer patients, with the ...
Source: Current Opinion in Oncology - Category: Cancer & Oncology Tags: GASTROINTESTINAL TRACT: Edited by Alain Hendlisz and Francesco Sclafani Source Type: research
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Chemotherapy | Esophagus Cancer | Gastric (Stomach) Cancer | Gastroenterology | HER2 | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy